The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design
ACT-ONE试验是一项多中心、随机、双盲、安慰剂对照的剂量探索性研究，旨在评估合成代谢/分解代谢转化剂MT-102在伴有III期和IV期非小细胞肺癌和结直肠癌恶病质患者中的疗效：研究设计
期刊:
影响因子:
doi:10.1007/s13539-011-0046-2
Stewart Coats, Andrew J; Srinivasan, Venkatesan; Surendran, Jayaraman; Chiramana, Haritha; Vangipuram, Shankar R K G; Bhatt, Nirajkumar N; Jain, Minish; Shah, Sandip; Ali, Irfhan A B H; Fuang, Ho G; Hassan, Mohammed Z M; Beadle, John; Tilson, Julia; Kirwan, Bridget-Anne; Anker, Stefan D
